share_log

Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem 聘請了 Stonegate 醫療保健合作伙伴
GlobeNewswire ·  05/07 20:00

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate's extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona's anti-aging ingredient, GlycoProteMimTM, to effectively assess and demonstrate its market potential within the global anti-aging skincare industry.

不列顛哥倫比亞省溫哥華,2024年5月7日(環球新聞專線)——Sirona Biochem Corp.(多倫多證券交易所股票代碼:SBM)(FSE:ZSB)(場外交易代碼:SRBCF)宣佈與Stonegate Healthcare Partners建立合作伙伴關係。Stonegate是一家領先的企業諮詢公司,總部位於德克薩斯州達拉斯,提供以研究爲導向的業務發展和投資者宣傳服務。利用Stonegate廣泛的全球企業和機構投資者關係網絡,Stonegate已開始評估Sirona的抗衰老成分GlycoProtemimTM,以有效評估和展示其在全球抗衰老護膚行業中的市場潛力。

About Sirona Biochem Corp.

關於 Sirona Biochem Corp.

Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona是一家擁有專有平台技術的化妝品原料和藥物研發公司。Sirona 專門穩定碳水化合物分子,目標是提高功效和安全性。新化合物已獲得專利,可最大限度地提高收入潛力。

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit .

Sirona的化合物已獲得全球領先公司的許可,以換取許可費、里程碑費和持續的特許權使用費。Sirona的實驗室TfChem位於法國,獲得了多項法國國家科學獎項以及歐盟和法國政府的資助。欲了解更多信息,請訪問。

About Stonegate Healthare Partners

Stonegate 醫療保健合作伙伴簡介

Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Investor Outreach, and Business Development. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies.

我們在Stonegate Healthcare Partners的使命是通過戰略、市場情報、投資者宣傳和業務發展,加速醫療保健領域的有意義的創新。該公司的研究方法以特定醫療領域的全面和比較分析爲中心。我們努力確定與我們的太空戰略願景密切相關的項目,並專注於最具顛覆潛力的技術。Stonegate Healthcare 建立在其基礎主題研究的基礎上,不斷收集市場情報,進一步了解當前未滿足的需求和新興的顛覆性技術。

Our affiliates Stonegate Capital Partners and Stonegate Capital Markets (Member FINRA/SIPC) provide institutional investor and business development outreach, and also equity research and investment banking advisory services. More information can be found at

我們的附屬公司Stonegate Capital Partners和Stonegate Capital Markets(成員FINRA/SIPC)提供機構投資者和業務發展宣傳以及股票研究和投資銀行諮詢服務。更多信息可以在以下網址找到

With five decades of experience and over 2500 institutional relationships, Stonegate currently works with ~80 public companies across a variety of sectors, and market caps for US and non-US listed companies. Our team is composed of investment bankers, former IROs, institutional salesmen, and research analysts who have extensive institutional relationships. We have built an unparalleled platform for public companies seeking to better build and manage their institutional and corporate relationships.

Stonegate擁有五十年的經驗和超過2500個機構關係,目前與各行各業的約80家上市公司合作,爲美國和非美國上市公司提供市值。我們的團隊由投資銀行家、前IRO、機構銷售員和具有廣泛機構關係的研究分析師組成。我們爲尋求更好地建立和管理其機構和公司關係的上市公司建立了一個無與倫比的平台。

About GlycoProteMimTM

關於 GlycoprotemimTM

GlycoProteMim, a novel anti-aging compound, was developed under the direction of Dr. Géraldine Deliencourt-Godefroy, using chemistry inspired by nature. This compound has been clinically validated as a significant breakthrough in non-invasive anti-aging skincare, offering powerful rejuvenation for aged skin. Safe, effective, and easy to use, GlycoProteMim could either complement or serve as an alternative to Botox and dermal fillers, depending on consumer preferences. Plans are in place to launch the first consumer product containing GlycoProteMim in Europe and North America through a subsidiary, Sirona Laboratories, in early 2025, with further expansions into other markets anticipated. More information can be found at

Glycoprotemim是一種新型的抗衰老化合物,是在傑拉爾丁·德利恩庫爾特-戈德弗洛伊博士的指導下開發的,使用了受自然啓發的化學物質。該化合物已被臨床驗證爲非侵入性抗衰老護膚的重大突破,可爲衰老的皮膚提供強大的恢復活力。GlycoProtemim 安全、有效且易於使用,可以補充肉毒桿菌毒素和皮膚填充劑或替代品,具體取決於消費者的喜好。計劃於2025年初通過子公司西羅納實驗室在歐洲和北美推出首款含有Glycoprotemim的消費品,預計還將進一步擴展到其他市場。更多信息可以在以下網址找到

For more information regarding this press release, please contact:

有關本新聞稿的更多信息,請聯繫:

Investor Enquiries:

投資者查詢:

Christopher Hopton
Chief Financial Officer

克里斯托弗·霍普頓
首席財務官

Phone: (604) 641-4466
Email: info@sironabiochem.com

電話:(604) 641-4466
電子郵件: info@sironabiochem.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Forward-Looking Statements

前瞻性陳述

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

本新聞稿包括某些可能被視爲 “前瞻性陳述” 的陳述。除歷史事實陳述外,本新新聞稿中涉及公司預計將發生的事件或事態發展的所有陳述均爲前瞻性陳述。前瞻性陳述不是歷史事實,通常但並非總是以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛在” 和類似表達方式來識別,或者說事件或條件 “將”、“將”、“可能” 或 “應該” 發生。儘管公司認爲此類前瞻性陳述中表達的預期是基於合理的假設,但此類陳述並不能保證未來的業績,實際業績可能與前瞻性陳述中存在重大差異。可能導致實際業績與前瞻性陳述中存在重大差異的因素包括市場價格、資本和融資的持續可用性以及總體經濟、市場或商業狀況。提醒投資者,任何此類陳述都不能保證未來的業績,實際業績或發展可能與前瞻性陳述中的預測存在重大差異。前瞻性陳述基於公司管理層在陳述發表之日的信念、估計和觀點。除非適用的證券法有要求,否則如果管理層的信念、估計或觀點或其他因素髮生變化,公司沒有義務更新這些前瞻性陳述。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論